Elicio Therapeutics, Inc.
- ELTX
- NASDAQ
- Biotechnology
- Cancer Immunotherapy
- Therapeutic Vaccines
- Immuno-oncology
$1.55
Today −0.64%Quote Oct 19, 2026, 08:00 PM UTC
−16.58%over the last month
Max drawdown −18.7%From 1-month high −18.7%3 months −48.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Elicio Therapeutics
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
33
Market value
$40.7M
Quote Oct 19
Floor
$1.55
0.2% below price
Resistance
$1.64
6.0% above price
Price vs analyst targets
4 analysts
Lowest target
$1.50Highest target
$17.00
$1.50Highest target
$17.00
- Price $1.55
- Average target $11.83
- Analysts' target range
The price is close to the lowest analyst target. Analysts' average target sits about 663% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ELTXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free